A. V. Zorinova

A. V. Zorinova

Auto-generated profile, based on publicly available information

A. V. Zorinova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2024 in Malignant tumours
Verified
Journal Article
Open access
ALA. N. Letuchikh
A. N. Letuchikh
AAA. S. Ablyametova
A. S. Ablyametova
AZA. V. Zorinova
A. V. Zorinova
EIE. R. Israelyan
E. R. Israelyan
ATA. S. Tsareva
A. S. Tsareva
ARA. A. Rumyantsev
A. A. Rumyantsev
The treatment approach for gestational and non-gestational ovarian choriocarcinoma has several differences, and their differential diagnosis requires special attention. The implementation of molecular-genetic testing which determines the presence of paternal genetic material in the tumor allows for a reliable determination of the origin of ovarian choriocarcinoma. The presented clinical case demonstrates the importance of this method in the differential diagnosis of gestational and non-gestational forms of ovarian choriocarcinoma.

18 December 2024 in Malignant tumours
Verified
Journal Article
Open access
PDF file
AAA. S. Ablyametova
A. S. Ablyametova
AZA. V. Zorinova
A. V. Zorinova
ALA. N. Letuchikh
A. N. Letuchikh
EIE. R. Israelyan
E. R. Israelyan
ATA. S. Tsareva
A. S. Tsareva
ARA. A. Rumyantsev
A. A. Rumyantsev
There is a cohort of cancer patients with terminal chronic kidney disease (CKD) due to various causes and requiring hemodialysis. Antitumor drug therapy in this concomitant disease is possible, but requires selection of the most optimal modified chemotherapy (CT) regimens to maximize efficacy and minimize treatment toxicity. In this case report we describe our therapeutic approach for a patient on hemodialysis with a metastatic non-seminomatous germ cell tumor (GCT) of the testis of poor prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification. We analyzed the literature datareflecting the use of different drugs and CT regimens used for the treatment of GCT in patients with CKD.

26 October 2026 in Surgery and Oncology
Verified
Journal Article
Open access
ALAngelina N. Letuchikh
Angelina N. Letuchikh
ARA. А. Rumyantsev
A. А. Rumyantsev
EIE. R. Israelyan
E. R. Israelyan
AAA. S. Ablyametova
A. S. Ablyametova
ATA. V. Trusova
A. V. Trusova
ASAleksandr Sultanbaev
Aleksandr Sultanbaev
Introduction. The combination of pembrolizumab and lenvatinib is the preferred second-line treatment for patients with recurrent endometrial cancer (EC) with proficient mismatch repair (pMMR) after platinum-based chemotherapy (CT). However, in real-world clinical practice, this option may be unavailable for some patients. Objective. To evaluate the efficacy of pembrolizumab plus lenvatinib compared with alternative СT regimens in patients with recurrent EC with pMMR tumor status upon progression after platinum based CT. Materials and Methods. A multicenter retrospective cohort study was conducted, including treatment data from patients with advanced and recurrent EC with рMMR tumor status from 37 oncology centers in Russia between December 2020 and December 2025. Patients were assigned to two groups according to the therapy received: immuno-targeted therapy (ITT) consisting of pembrolizumab plus lenvatinib, and alternative CT regimens, which included either platinum-based CT reinduction or non-platinum-based CT. To minimize the impact of baseline characteristic differences between the groups, patients were matched using cardinality matching (matching with maximization of the balanced sample size) at a 1:1 ratio. Group balancing was performed for the following variables: age, histological subtype, stage IV disease, receipt of radical/palliative surgery as first-line treatment, and platinum-free interval (PFI). The standardized mean difference was within ≤0.1 in absolute value for all variables. The primary endpoint was progression-free survival (PFS). Results. A total of 173 patients were enrolled in the study, of whom 106 constituted the ITT group and 67 constituted the CT group. From the initial study population, after cardinality matching, two groups of 67 patients each were formed. The median age was 60 (range, 36–80) years in the ITT group and 61 (range, 37–79) years in the alternative CT group; primary surgery was performed in 61/67 (91%) and 62/67 (93%) of patients, respectively. The median PFI was 6.9 (range, 0.0–106.5) months in the pembrolizumab–lenvatinib combination group and 9.1 (range, 0.0–69.0) months in the control group. At a median follow-up of 36.1 months (95% CI, 31.8–42.6), the median PFS in the ITT group was 9.9 months (95% CI, 7.2–12.9) versus 6.8 months (95% CI, 4.7–8.3) in the alternative CT group, which was statistically significant (HR 0.58; 95% CI, 0.40–0.85; p = 0.005). Conclusions. Treatment with the combination of pembrolizumab and lenvatinib is associated with longer PFS compared with alternative CT regimens in the matched cohort of patients with recurrent and advanced EC with MSS/pMMR tumor status upon progression after platinum-based CT.

26 October 2026 in Surgery and Oncology
Verified
Journal Article
Open access
ATAlina V. Trusova
Alina V. Trusova
ARA. A. Rumyantsev
A. A. Rumyantsev
EIE. R. Israelyan
E. R. Israelyan
ATA. S. Tsareva
A. S. Tsareva
AAA. S. Ablyametova
A. S. Ablyametova
SKSvetlana Khokhlova
Svetlana Khokhlova
Introduction. The current standard of care for metastatic and recurrent cervical cancer (CC) is platinum- and taxane-based chemotherapy (CT). However, the choice of platinum agent remains a subject of debate. Objective. To compare the efficacy of cisplatin- and carboplatin-containing CT regimens in the first-line treatment of advanced CC. Materials and Methods. A multicenter comparative retrospective study using a pseudorandomization method (PSM analysis) was conducted, including patients with metastatic and recurrent CC who received first-line platinum-based therapy (cisplatin or carboplatin) between 2010 and 2025. The use of immunotherapy and bevacizumab in first-line therapy was permitted. Patients who received neoadjuvant/adjuvant CT were excluded. An analysis was performed using the cardinality matching (CM) method with the MatchIT package in R, balancing the groups on key covariates (age, bevacizumab, immunotherapy, history of bleeding, treatment-free interval, and presence of pelvic recurrence) at a 2:1 ratio. The standardized mean difference did not exceed 0.1 in absolute value in all cases. The primary endpoint of the study is progression-free survival (PFS); secondary endpoints are overall survival (OS) and treatment safety. Results. The study included 437 patients. After CM analysis, the carboplatin group included 228 patients, and the cisplatin group included 114 patients. The predominant histotype was squamous cell carcinoma (82.5% and 78.5%, respectively). Stage IV at baseline was observed in 37 (32.5%) and 79 (34.6%) patients. The most common metastatic site was lymph nodes, in 79 (69.3%) and 129 (56.6%) patients, respectively. At a median follow-up of 32.5 (1–141.6) months, median PFS (mPFS) was 8.27 (95% CI 7.7–9.2) mo in the carboplatin group and 8.57 (95% CI 7.5–10.4) mo in the cisplatin group; median OS (mOS) was 23.7 (95% CI 18–35) mo and 33.43 (95% CI 25.5–59.8) mo respectively. No statistically significant difference was found in mPFS (HR 0.84; 95% CI 0.66–1.1; p = 0.185) or mOS (HR 0.76; 95% CI 0.56–1.05; p = 0.100) between the groups. Carboplatin use was associated with a higher incidence of hematologic toxicity (р = 0.301), while cisplatin was associated with more vomiting (р = 0.181), diarrhea (р = 0.359), and nephrotoxicity (р = 0.004). Conclusion. The results of this retrospective study with PSM analysis showed no statistically significant difference in the efficacy of cisplatin versus carboplatin in combination with paclitaxel for metastatic and recurrent CC, with a more favorable toxicity profile for the former platinum agent.